Rapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and ATM Mutation: A Case Report
ABSTRACT: Managing pediatric Crohn's disease (PCD) presents challenges due to severe complications and higher biologic therapy needs. Transitioning from anti–tumor necrosis factor agents to off-label therapies adds complexity. Although upadacitinib has demonstrated efficacy and tolerability in...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Current Therapeutic Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0011393X24000262 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850255644111667200 |
|---|---|
| author | Yan Liu, MD XiaoMei Song, MD LingYa Xiang, MD Wei Tan, MD Min Zou, MD Hong Guo, MD |
| author_facet | Yan Liu, MD XiaoMei Song, MD LingYa Xiang, MD Wei Tan, MD Min Zou, MD Hong Guo, MD |
| author_sort | Yan Liu, MD |
| collection | DOAJ |
| description | ABSTRACT: Managing pediatric Crohn's disease (PCD) presents challenges due to severe complications and higher biologic therapy needs. Transitioning from anti–tumor necrosis factor agents to off-label therapies adds complexity. Although upadacitinib has demonstrated efficacy and tolerability in adult inflammatory bowel disease and pediatric atopic dermatitis, there are limited data for its application in PCD. This case report delineates successful remission with upadacitinib in a child with CD refractory to infliximab, ustekinumab, adalimumab, thalidomide, and prednisone. Notably, the patient carried an ataxia telangiectasia mutated (ATM) gene mutation. These findings provide valuable evidence for PCD management and highlight the potential benefits of upadacitinib in this population. |
| format | Article |
| id | doaj-art-ab6ab36dca754b9492caee53f265cb5f |
| institution | OA Journals |
| issn | 0011-393X |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Therapeutic Research |
| spelling | doaj-art-ab6ab36dca754b9492caee53f265cb5f2025-08-20T01:56:49ZengElsevierCurrent Therapeutic Research0011-393X2024-01-0110110075610.1016/j.curtheres.2024.100756Rapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and ATM Mutation: A Case ReportYan Liu, MD0XiaoMei Song, MD1LingYa Xiang, MD2Wei Tan, MD3Min Zou, MD4Hong Guo, MD5Department of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, ChinaDepartment of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, ChinaDepartment of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, ChinaDepartment of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, ChinaDepartment of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, ChinaAddress correspondence to: Hong Guo, MD, Chongqing General Hospital, 118, Xingguang Avenue, Liangjiang New Area, Chongqing, 401147, China.; Department of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, ChinaABSTRACT: Managing pediatric Crohn's disease (PCD) presents challenges due to severe complications and higher biologic therapy needs. Transitioning from anti–tumor necrosis factor agents to off-label therapies adds complexity. Although upadacitinib has demonstrated efficacy and tolerability in adult inflammatory bowel disease and pediatric atopic dermatitis, there are limited data for its application in PCD. This case report delineates successful remission with upadacitinib in a child with CD refractory to infliximab, ustekinumab, adalimumab, thalidomide, and prednisone. Notably, the patient carried an ataxia telangiectasia mutated (ATM) gene mutation. These findings provide valuable evidence for PCD management and highlight the potential benefits of upadacitinib in this population.http://www.sciencedirect.com/science/article/pii/S0011393X24000262ataxia telangiectasia mutatedcase reportchildrefractory Crohn's diseaseupadacitinib |
| spellingShingle | Yan Liu, MD XiaoMei Song, MD LingYa Xiang, MD Wei Tan, MD Min Zou, MD Hong Guo, MD Rapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and ATM Mutation: A Case Report Current Therapeutic Research ataxia telangiectasia mutated case report child refractory Crohn's disease upadacitinib |
| title | Rapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and ATM Mutation: A Case Report |
| title_full | Rapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and ATM Mutation: A Case Report |
| title_fullStr | Rapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and ATM Mutation: A Case Report |
| title_full_unstemmed | Rapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and ATM Mutation: A Case Report |
| title_short | Rapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and ATM Mutation: A Case Report |
| title_sort | rapid remission with upadacitinib in a child with refractory crohn s disease and atm mutation a case report |
| topic | ataxia telangiectasia mutated case report child refractory Crohn's disease upadacitinib |
| url | http://www.sciencedirect.com/science/article/pii/S0011393X24000262 |
| work_keys_str_mv | AT yanliumd rapidremissionwithupadacitinibinachildwithrefractorycrohnsdiseaseandatmmutationacasereport AT xiaomeisongmd rapidremissionwithupadacitinibinachildwithrefractorycrohnsdiseaseandatmmutationacasereport AT lingyaxiangmd rapidremissionwithupadacitinibinachildwithrefractorycrohnsdiseaseandatmmutationacasereport AT weitanmd rapidremissionwithupadacitinibinachildwithrefractorycrohnsdiseaseandatmmutationacasereport AT minzoumd rapidremissionwithupadacitinibinachildwithrefractorycrohnsdiseaseandatmmutationacasereport AT hongguomd rapidremissionwithupadacitinibinachildwithrefractorycrohnsdiseaseandatmmutationacasereport |